跳至主要内容
临床试验/NCT04306978
NCT04306978Unknown不适用

Impact of the CareLink Express Remote Monitoring System on Early Detection of Atrial Fibrillation and Cardiovascular Risk Reduction in Patients With Implantable Cardiac Pacemakers

Research Institute for Complex Problems of Cardiovascular Diseases, Russia2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2017年9月21日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
200
试验地点
2
主要终点
time (days) from the pacemaker system implantation to the first AF episode detected by ESG or EGM

研究概览

简要总结

The study results will be used to check the hypothesis that CareLink Express remote monitoring system increases the detection rate of asymptomatic AF and allows to change timely the treatment strategy in patients at high risk of thromboembolic events, e.g. anticoagulation therapy onset, electrical cardioversion or/and PVI.

详细描述

It is expected to enroll 200 consecutive patients without previously diagnosed AF, who have indications for implantation of dual chamber cardiac pacemakers according to the current guidelines. All the patients will be randomly assigned into 2 groups. Patients in the RM group will undergo the implantation of Ensura DR MRI SureScan pacing system, whereas patients in the control group will receive ADAPTA DR pacing system without RM using. The impact of the Care Link Express service on prevention of thromboembolism will be evaluated. The rate of in-hospital visits for 1 patient per year and compliance with scheduled CareLink transmissions (ratio of the number of the performed transmissions to the planned ones) will be assessed in all patients in the remote monitoring group. Moreover, we are going to estimate the interaction between the follow-up center and other healthcare facilities equipped with the CareLink Express service, which will facilitate faster treatment decision.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with indications for implantation of dual chamber cardiac pacemaker
  • patients with no AF history;
  • written informed consent.

排除标准

  • patients with contraindications for CIED implantation;
  • patients with previously implanted CIEDs;
  • infection;
  • patients with previously diagnosed AF

结局指标

主要结局

time (days) from the pacemaker system implantation to the first AF episode detected by ESG or EGM

时间窗: 24 months

the episode should be evaluated by the follow-up clinic physician(s) and meet the appropriate criteria (irregular RR intervals and distinct P waves, ≥30s episode duration)

次要结局

  • the number of non-planned induced visits in the follow-up center(24 months)
  • correction in the medical therapy(24 months)
  • cardioversion(24 months)
  • all-cause mortality(24 months)
  • catheter/surgical PVI(24 months)
  • thromboembolic events(24 months)
  • hospitalization for cardiovascular events(24 months)

研究者

发起方
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Sergey Mamchur

Head of Department of Diagnosis of Cardiovascular Diseases

Research Institute for Complex Problems of Cardiovascular Diseases, Russia

研究点 (2)

Loading locations...

相似试验